Ipsen to Present New Insights at ASBMR for Potential Treatment of Ultra-rare Disease Fibrodysplasia Ossificans Progressiva (FOP), Including Global Phase III MOVE Trial Results
Biospace,
Sept. 10, 2020 05:00 UTC Seven presentations represent Ipsen’s largest presence to date at ASBMR, the world’s leading…